Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The topping out ceremony marks a milestone in the Holly Springs facility’s development.
August 19, 2026
By: Patrick Lavery
Editor’s Take: This construction underscores Genentech’s confidence in the regional workforce and long-term potential.
Genentech on Aug. 18 raised the final beam of its new Holly Springs, NC manufacturing facility, marking structural framework completion. Holly Springs, and the wider Raleigh–Durham region, has been growing as a biopharmaceutical manufacturing and innovation hub.
The topping out ceremony was a construction milestone for Genentech, which is a member of the Roche Group. The company says it reflects on-time progress for its approximate $2 billion investment.
When completed, the manufacturing facility will be Genentech’s first on the East Coast of the United States. Initial announcement of this project came in May 2025, with groundbreaking in August of 2025 and expansion in January 2026.
More broadly, Roche and Genentech are committing $50 billion to R&D and manufacturing infrastructure in the U.S. Currently, this footprint encompasses 13 manufacturing sites, 15 R&D sites, and 25,000 employees in 24 overall locations in eight states.
The Holly Springs facility should eventually support over 2000 jobs: more than 500 high-wage manufacturing positions, and 1500 construction openings.
The facility intends to produce next-generation treatments for metabolic conditions like obesity. Advanced biomanufacturing, automation, robotics, and up-to-date digital manufacturing technologies will support production efficiency, sustainability, and strengthen the U.S. supply chain.
Regarding Genentech’s investment on the technology side, the facility will feature an advanced digital twin. This AI-powered, data-driven model simulates operations and tests scenarios prior to real-world implementation.
To support its anticipated new workforce, Genentech will partner with academic institutions local to the Raleigh–Durham area. This will prepare talent for manufacturing careers in such areas as AI, robotics, automation, and advanced biomanufacturing.
Genentech says the construction milestone reflects its confidence in Holly Springs’ workforce, community, and long-term potential.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
